GLP-1 Efficacy & Outcomes

Do I need to exercise on Wegovy?

Yes — resistance training specifically. Without it, 25-40% of weight lost on GLP-1 comes from lean muscle. Cardio is a bonus; resistance is

How fast do results show on GLP-1?

Appetite changes in 1-2 weeks. Visible weight loss usually starts in week 4-6. Significant fat loss accelerates in weeks 12-44 as the dose e

Why am I not losing weight on Wegovy?

Most non-responders fall into 4 buckets: dose hasn't reached maintenance (2.4 mg), titration was interrupted, calorie intake creeps to match

Can I build muscle on a GLP-1?

Yes — with deliberate resistance training and adequate protein. Without it, 25-40% of weight lost on GLP-1 comes from lean muscle. Lifting 2

Can GLP-1 help with PCOS?

Yes — primarily via weight loss and improved insulin sensitivity. Smaller trials show improved ovulatory cycles and reduced androgen symptom

Does GLP-1 work for type 1 diabetes?

No GLP-1 is FDA-approved for type 1 diabetes. Some endocrinologists prescribe semaglutide off-label as an insulin adjunct in T1D with obesit

How does Wegovy compare to Saxenda?

Both are GLP-1 agonists from Novo Nordisk. Wegovy (semaglutide, weekly) produces ~15% mean weight loss; Saxenda (liraglutide, daily) produce

Can teenagers take GLP-1 medications?

Yes — Wegovy is FDA-approved for ages 12+ with BMI ≥95th percentile for age. Saxenda is approved 12+ with BMI ≥30 kg/m² equivalent. Zepbound

Will I regain weight after stopping GLP-1?

Most people regain about two-thirds of lost weight within 1 year of stopping, based on STEP-1 extension and STEP-4 withdrawal data. Continue

Can GLP-1 help with sleep apnea?

Yes. Zepbound (tirzepatide) became the first medication FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity (

Can I take GLP-1 after bariatric surgery?

Yes, in many cases. Post-bariatric weight regain affects 20-30% of patients within 2-5 years. GLP-1 added to bariatric surgery (sleeve, RYGB

Does GLP-1 work without diet changes?

Some weight loss happens regardless — appetite is reduced enough that calories drop naturally. But the trial-magnitude weight loss (10-22%)

Is GLP-1 safe with kidney disease?

Yes for most patients with CKD stages 1-3. Semaglutide has FLOW trial data showing kidney protection. Doses do not require renal adjustment.

Can I switch from Wegovy to Zepbound?

Yes, and many patients do — SURMOUNT-5 (NEJM 2025) showed tirzepatide produced 20% mean weight loss vs 14% for semaglutide. Switching is usu

Does GLP-1 help with fatty liver (NAFLD/NASH)?

Yes. Multiple GLP-1 trials show liver-fat reduction and improvement in fibrosis markers. Tirzepatide (SYNERGY-NASH, NEJM 2024) achieved NASH

Does GLP-1 improve cholesterol?

Yes, modestly. GLP-1 medications reduce triglycerides 10-20%, LDL 5-10%, and ApoB ~7%. Most of the effect comes from weight loss, but a smal

Can GLP-1 help with binge eating disorder?

Promising preliminary evidence. Small RCTs and case series show GLP-1 reduces binge frequency and food-reward cravings in adults with BED. N

Does GLP-1 affect fertility?

In adults with PCOS or obesity-related infertility, GLP-1-mediated weight loss often improves ovulation and fertility. There is anecdotal "O

Does GLP-1 prevent heart attacks?

Yes for semaglutide — SELECT (NEJM 2023) showed a 20% reduction in major adverse cardiovascular events (MACE: heart attack, stroke, CV death

Is Rybelsus (oral semaglutide) as effective as Ozempic (injectable)?

Rybelsus 14 mg daily is roughly equivalent to Ozempic 0.5 mg weekly for A1c reduction. For weight loss, injectable doses (up to 2.4 mg Wegov

Can GLP-1 help with alcohol or opioid use disorder?

Promising preliminary signal for both. GLP-1 acts on brain reward circuits that overlap with addiction pathways. Several RCTs in alcohol use

STEP-1: Semaglutide Treatment Effect in People with Obesity — 1

−14.9% mean body-weight reduction on semaglutide vs −2.4% placebo (P<0.001)

SURMOUNT-1: A Study of Tirzepatide in Participants with Obesity or Overweight

−15.0% (5 mg), −19.5% (10 mg), −20.9% (15 mg) on tirzepatide vs −3.1% placebo

SUSTAIN-6: Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

26% relative reduction in MACE on semaglutide vs placebo (HR 0.74, 95% CI 0.58-0.95; P=0.02 for non-inferiority and superiority)

SELECT: Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity

20% relative reduction in MACE on semaglutide 2.4 mg vs placebo (HR 0.80, 95% CI 0.72-0.90; P<0.001)

SURPASS-2: A Study of Tirzepatide versus Semaglutide in Participants with Type 2 Diabetes

Tirzepatide superior at all three doses: −2.01% (5 mg), −2.24% (10 mg), −2.30% (15 mg) vs −1.86% semaglutide 1 mg

FLOW: A Research Study to See How Semaglutide Works Compared to Placebo in People with Type 2 Diabetes and Chronic Kidney Disease

24% relative reduction in primary composite on semaglutide vs placebo (HR 0.76, 95% CI 0.66-0.88; P<0.001)

SURMOUNT-OSA: A Study of Tirzepatide in Adults with Obesity and Moderate-to-Severe Obstructive Sleep Apnea

−25 to −29 events/hour mean reduction on tirzepatide vs −5 events/hour placebo

SURMOUNT-4: Tirzepatide Maintenance — Continued versus Withdrawn

Continued tirzepatide: additional −5.5% weight loss. Withdrawn to placebo: regained 14% of body weight by week 88 (about 2/3 of weight previ

FDA approves Wegovy HD — higher-dose semaglutide for sustained weight loss

Novo Nordisk receives FDA approval for Wegovy HD (semaglutide 7.2 mg weekly). Phase-3 STEP-UP data shows ~20% weight loss at 68 weeks. Launc

NICE expands tirzepatide weight-management eligibility in England (TA1026 update)

National Institute for Health and Care Excellence (NICE) revised TA1026 May 2026, lowering the BMI threshold to ≥30 (from ≥35) for NHS-funde

Foundayo (orforglipron) — first oral non-peptide GLP-1 — launches in US

Eli Lilly launched Foundayo (orforglipron 36 mg daily tablet) for chronic weight management on May 5, 2026. Phase-3 ATTAIN-1 showed ~12.4% m

Wegovy Diary Month 1: the first injection, peak nausea, food noise quiet

A composite first-month chronicle of starting Wegovy at 0.25 mg. What injection day actually feels like, when the food noise drops, and what

Wegovy Diary Month 2: the boring middle, first restaurant test, the scale catches up

Month 2 is when the routine settles. I'm at 0.5 mg, the food noise is permanently quieter, and I have my first real-restaurant test. The res

Wegovy Diary Month 3: 1.0 mg settles in, the friends-and-family question, body composition changes

Month 3 at 1.0 mg. The questions from people I haven't seen in a while start. I take my first DEXA scan and the body composition surprises m

Wegovy Diary Month 4: 1.7 mg dose, plateau scare, the social trip

Month 4 introduces 1.7 mg, my first scale plateau, and a 5-day work trip with restaurant meals every night. Here's how each tested the routi

Zepbound Diary Month 1: starter dose, dual-receptor effect, the appetite shift

First month on Zepbound at 2.5 mg. The dual GIP/GLP-1 mechanism shows up differently — appetite doesn't just shut down, it shifts. Here's th

Zepbound Diary Month 2: 5 mg therapeutic dose, the appetite settles, first 10 lb threshold

Month 2 on Zepbound at 5 mg. The dual-receptor effect compounds. I cross the first 10 lb threshold and start noticing the things that don't